Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403529 | 0.83 | APEX1 (0.50) | HPGDALDH1A1GAAAPEX1MRGPRX4 | |
| SCHEMBL4217682 | 0.76 | MAPT (0.77) | CYP1A2CYP3A4CYP2C19MAPTALDH1A1 | |
| SCHEMBL586740 | 0.76 | DTYMK (0.48) | MAPTALDH1A1POLBHTR6KMT2A | |
| SCHEMBL11248670 | 0.75 | HIF1A (0.58) | MAPTPOLBMRGPRX4 | |
| SCHEMBL7373815 | 0.75 | CDK5 (0.53) | CYP1A2CYP3A4HPGDCYP2C19MAPT | |
| SCHEMBL1403476 | 0.74 | KMT2A (0.48) | MAPTALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL475545 | 0.74 | HTR6 (0.57) | CYP1A2CYP3A4CYP2C19MAPTALDH1A1 | |
| SCHEMBL79163 | 0.74 | DTYMK (0.62) | CYP1A2CYP3A4HPGDCYP2C19ALDH1A1 | |
| SCHEMBL13802457 | 0.74 | MRGPRX4 (0.63) | NPC1RAB9AMRGPRX4 | |
| Hydrochloric Acid SCHEMBL1748343 | 0.73 | HTR6 (0.59) | CYP1A2CYP3A4CYP2C19MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CYP1A2 461/4885CYP3A4 1396/4885HPGD 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.